Skip to main content
HRES 525 110th Congress House Foreign Trade and International Finance Access to health care Commerce Developing countries Drug industry Drugs Free trade Generic drugs Health Intellectual property International Affairs Medical research Patents Pharmaceutical research Research and development Science, Technology, Communications Trade agreements

Expressing the sense of the House of Representatives that the United States should reaffirm the commitments of the United States to the 2001 Doha Declaration on the TRIPS Agreement and Public Health and to pursuing trade policies that promote access to affordable medicines.

Introduced: June 28, 2007 See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 6, 2007
Referred to the Subcommittee on Trade.
Jun 28, 2007
Referred to the House Committee on Ways and Means.
Jun 28, 2007
Introduced in House
 Plain-English summary Congressional Research Service

Urges the United States to: (1) honor U.S. commitments made in the 2001 World Trade Organization Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and Public Health, which allows World Trade Organization (WTO) members to fully use the flexibilities in the TRIPS Agreement to protect public health and promote access to medicines for all; (2) not place countries on the "Special 301" Priority Watch List for exercising such flexibilites, such as issuing compulsory licenses to obtain generic medicines; (3) not ask developing countries that are trading partners to adopt measures to protect public health intellectual property rights in excess of protections required in the TRIPS Agreement; and (4) support new global norms for promoting medical research and development.

What's happening now July 6, 2007

Referred to the Subcommittee on Trade.

 Committees of jurisdiction 2